CTOs on the Move

Nereid Therapeutics

www.nereidtx.com

 
Nereid Therapeutics, an ATP company, is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and resulting biomolecular condensates.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.nereidtx.com
  • 245 Main Street Floor !2
    Boston, MA USA 02142
  • Phone: 617.294.6790

Executives

Name Title Contact Details

Funding

Nereid Therapeutics raised $50M on 11/16/2020

Similar Companies

HudsonAlpha Institute for Biotechnology

HudsonAlpha Institute seeks to expand the science of human genomics and hasten its movement into the marketplace where discoveries can benefit society.

Kinnos

Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.

Cryofab

Cryofab is a Kenilworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biotech Medical

Biotech Medical is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pillar Biosciences

Pillar Biosciences aims to "Make precision medicine the first option for every patient" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today`s high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%. Current as of May 25, 2021.